Showing results (111-120 of 119) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 119 results.
NPJ Vaccines|March 16, 2021
Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancerJanos L Tanyi, Cheryl L-L Chiang, Johanna Chiffelle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2022
BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant MelanomaJanice M Mehnert, Tara C Mitchell, Alexander C Huang, et al.
Nature|March 11, 2015
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancerChristina Twyman-Saint Victor, Andrew J Rech, Amit Maity, et al.
Science Translational Medicine|April 13, 2018
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancerJanos L Tanyi, Sara Bobisse, Eran Ophir, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2021
Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic CancerKatelyn T Byrne, Courtney B Betts, Rosemarie Mick, et al.
The Lancet. Oncology|January 2, 2021
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b studyMark H O'Hara, Eileen M O'Reilly, Gauri Varadhachary, et al.
Nature|April 12, 2017
T-cell invigoration to tumour burden ratio associated with anti-PD-1 responseAlexander C Huang, Michael A Postow, Robert J Orlowski, et al.
Nature Medicine|February 27, 2019
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanomaAlexander C Huang, Robert J Orlowski, Xiaowei Xu, et al.
Nature Medicine|June 6, 2022
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trialLacey J Padrón, Deena M Maurer, Mark H O'Hara, et al.
Pageof 12